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Figure 1. Adjusted survival curves
associated with worse survival from all-cause mortality was >35 mmHg and the
mortality rate increased with increased sPAP.
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Background: Pulmonary artery (PA) dilation is a common consequence of pul-
monary hypertension (PH) and it may reach aneurysmal dimensions. Compres-
sion of the left main coronary artery (LMCA) is a rare complication of PA dilation.
Data on its diagnosis, management and outcomes are scarce.
Purpose: We report the clinical characteristics and outcomes of PH patients with
LMCA extrinsic compression in a single PH referral center.
Methods: All PAH patients referred to a single tertiary center were reviewed. Clini-
cal and imaging data were retrospectively obtained and patients with documented
LMCA compression on coronarography were selected.
Results: We report a series of 10 PH patients with LMCA compression, 8 fe-
males, mean age 42 (19–57) years at the time of the invasive diagnosis. Di-
agnoses included PH associated with congenital heart disease (n=8), chronic
postembolic PH associated with thrombophilia (n=1) and systemic sclerosis (n=1)
and a total of 5 patients were symptomatic for angina. The other 5 patients un-
derwent coronarography because of the severely dilated PA. Coronarography
showed LMCA pencil-tip-shape stenosis ranging from 30% to 90%. Significant
stenosis (>50%) was found in 6 patients and coronary angioplasty (PCI) was per-
formed in 2 cases (stenoses of 70% and 90%). The first patient underwent PCI
with a drug-eluting stent and was reevaluated for recurrent angina three years
later, when the stent was found to be permeable, but later died. The second pa-
tient was discharged after the procedure and died afterwards of unknown causes.
None of these two patients received specific PH therapy which was unavailable
at that time (2006) in our country. Associated coronary anomalies were identified
in 3 cases: a wide LMCA (7 mm), a right coronary artery – main PA fistula, a
circumflex artery – left ventricle fistula. None of the fistulae were addressed (no
haemodynamic impact).
At initial evaluation echocardiography showed dilated PA in all 10 patients: mean
42.1 mm (range 33–73 mm), with a mean PA-to-aorta diameter ratio of 1.37. Car-
diac catheterisation revealed significant PH in all patients: average systolic and
mean PA pressures 101 (range 67–139) mmHg and 60 (range 40–91) mmHg, re-
spectively. There was no difference in PA diameter or pressures between patients
with or without significant LMCA stenosis.
There were 4 deaths in total during 10 years follow-up: both patients with PCI
Pencil-tip-shaped LMCA stenosis
(without specific PH therapy), one patient with a LMCA stenosis of 70% without
PCI and one with 40% stenosis due to terminal heart failure.
Conclusion: Left main coronary artery compression due to dilated PA in pul-
monary hypertension can be significant enough to require intervention. In our se-
ries, angioplasty was safely performed with symptomatic relief in these patients.
Further studies are needed to establish the role of screening for and treatment of
coronary extrinsic compression in patients with pulmonary hypertension.
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Introduction: Pulmonary hypertension (PH) comprises a group of progressive
diseases characterized by an increase in pulmonary vascular resistance, lead-
ing to right ventricular dysfunction. Risk stratification is essential for prognostic
evaluation and therapeutic decision, making the determination of new biomarkers
important.
Purpose: To assess the prognostic value of new biomarkers in the prognostic
evaluation of patients with PH.
Methods: Prospective cohort study of patients (pts) with PH confirmed by hemo-
dynamic evaluation.
Pts underwent clinical and laboratory evaluations at baseline and every 3
months. Follow-up lasted for 18 months. NTproBNP and the new biomark-
ers (adrenomedullin, copeptin and proenkephalin) were measured. The Mann-
Whitney test, Kaplan-Meier survival analysis and Cox regression were used for
statistical analysis.
Results: Fifty one pts (75% males, mean age: 54±15 years) belonging to all
groups of the WHO PH classification were included. At inclusion, all pts were in
WHO functional class II or III. During the study period, 17 pts (33%) died. Base-
line NTproBNP values were significantly higher in the non-survivors group (1327;
1061–2703pg/ml vs. 353.5; 190–1661pg/ml; p=0.022). The same did not occur
for adrenomedullin, copeptin and proenkephalin baseline levels. The maximum
NTproBNP, adrenomedullin and copeptin levels recorded during the follow-up pe-
riod were significantly higher in the non-survivors group [2347.5 (1667–5073.25)
pg/ml vs. 642.5 (208.25–4109.5) pg/ml, p=0.007; 53.6 (38.8- 94.2) pg/ml vs. 33.4
(27–48.8) pg/ml, p=0.0075; 20.69 (13.18–35.69) pmol/L vs. 9.97 (6.18–14.74)
pmol/L, p=0.022, respectively]. This did not occur for the maximum proenkephalin
level. The NT-proBNP level at admission and adremedullin level at 3 months were
independent predictors of mortality (HR 2.78, CI95 1.23–6.30, p=0.01; HR 4.36,
CI95 1.17–16.2, p=0.03).
Conclusion: The maximum level of NTproBNP, adrenomedullin and copeptin dur-
ing the follow up were associated with higher mortality in pts with PH. NTproBNP
level proved to be an independent predictor of mortality in those patients. These
results suggest the prognostic importance of these biomarkers in the approach of
pts with PH.
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Background: Cause of death in patients with idiopathic pulmonary hypertension
(IPAH) has not been extensively studied previously. In early clinical trials, the
mean age of enrolled IPAH patients has been under 65 years. However, more
recent reports show an increasing proportion of IPAH patients ≥65 years. Mortal-
ity among older compared to younger IPAH patients is very high. Whether PAH-
related death is less common in elderly than younger IPAH patients in not known.
Aim: The aim of this study was to investigate the cause of death and the effect of
comorbidity on survival in IPAH patients <65y compared to those ≥65y.
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